Esther M. Kooijman

Amsterdam, NH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 29 publications

Investigation of the Impact of the H310A FcRn Region Mutation on 89Zr-Immuno-PET Brain Imaging with a BBB-Shuttle Anti‑Amyloid Beta Antibody.

Investigation of the Impact of the H310A FcRn Region Mutation on 89Zr-Immuno-PET Brain Imaging with a BBB-Shuttle Anti‑Amyloid Beta Antibody.

Journal: Molecular imaging and biology

Published: January 16, 2024

Development of 18F-Labeled PET Tracer Candidates for Imaging of the Abelson Non-receptor Tyrosine Kinase in Parkinson's Disease.

Development of 18F-Labeled PET Tracer Candidates for Imaging of the Abelson Non-receptor Tyrosine Kinase in Parkinson's Disease.

Journal: Journal of medicinal chemistry

Published: September 15, 2023

Synthesis and Preclinical Evaluation of [Methylpiperazine-11C]brigatinib as a PET Tracer Targeting Both Mutated Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase.

Synthesis and Preclinical Evaluation of [Methylpiperazine-11C]brigatinib as a PET Tracer Targeting Both Mutated Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase.

Journal: Journal of medicinal chemistry

Published: August 30, 2023

Synthesis and preclinical evaluation of [11C]EAI045 as a PET tracer for imaging tumors expressing mutated epidermal growth factor receptor.

Synthesis and preclinical evaluation of [11C]EAI045 as a PET tracer for imaging tumors expressing mutated epidermal growth factor receptor.

Journal: EJNMMI research

Published: August 08, 2023

Synthesis and preclinical evaluation of two osimertinib isotopologues labeled with carbon-11 as PET tracers targeting the tyrosine kinase domain of the epidermal growth factor receptor.

Synthesis and preclinical evaluation of two osimertinib isotopologues labeled with carbon-11 as PET tracers targeting the tyrosine kinase domain of the epidermal growth factor receptor.

Journal: Nuclear medicine and biology

Published: February 22, 2023

Imaging the TGFβ type I receptor in pulmonary arterial hypertension.

Imaging the TGFβ type I receptor in pulmonary arterial hypertension.

Journal: EJNMMI research

Published: November 04, 2022

Application of 89Zr-DFO*-immuno-PET to assess improved target engagement of a bispecific anti-amyloid-ß monoclonal antibody.

Application of 89Zr-DFO*-immuno-PET to assess improved target engagement of a bispecific anti-amyloid-ß monoclonal antibody.

Journal: European journal of nuclear medicine and molecular imaging

Published: September 20, 2022

Advancing 89Zr-immuno-PET in neuroscience with a bispecific anti-amyloid-beta monoclonal antibody - The choice of chelator is essential.

Advancing 89Zr-immuno-PET in neuroscience with a bispecific anti-amyloid-beta monoclonal antibody - The choice of chelator is essential.

Journal: Theranostics

Published: April 01, 2022

Synthesis and preclinical evaluation of [11C]LR111 and [18F]EW-7197 as PET tracers of the activin-receptor like kinase-5.

Synthesis and preclinical evaluation of [11C]LR111 and [18F]EW-7197 as PET tracers of the activin-receptor like kinase-5.

Journal: Nuclear medicine and biology

Published: February 23, 2022

Correction to Novel Thienopyrimidine-Based PET Tracers for P2Y12 Receptor Imaging in the Brain.

Correction to Novel Thienopyrimidine-Based PET Tracers for P2Y12 Receptor Imaging in the Brain.

Journal: ACS chemical neuroscience

Published: February 22, 2022

Novel Thienopyrimidine-Based PET Tracers for P2Y12 Receptor Imaging in the Brain.

Novel Thienopyrimidine-Based PET Tracers for P2Y12 Receptor Imaging in the Brain.

Journal: ACS chemical neuroscience

Published: November 10, 2021

Synthesis and evaluation of [18F]cinacalcet for the imaging of parathyroid hyperplasia.

Synthesis and evaluation of [18F]cinacalcet for the imaging of parathyroid hyperplasia.

Journal: Nuclear medicine and biology

Published: June 07, 2021

Showing 1-12 of 29

Last Updated: 09/26/2026